These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 35851961)

  • 1. Differential avidity determination of IgG directed towards the receptor-binding domain (RBD) of SARS-CoV-2 wild-type and its variants in one assay: Rational tool for the assessment of protective immunity.
    Bauer G; Struck F; Staschik E; Maile J; Wochinz-Richter K; Motz M; Soutschek E
    J Med Virol; 2022 Nov; 94(11):5294-5303. PubMed ID: 35851961
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antibody Avidity and Neutralizing Response against SARS-CoV-2 Omicron Variant after Infection or Vaccination.
    Dapporto F; Marchi S; Leonardi M; Piu P; Lovreglio P; Decaro N; Buonvino N; Stufano A; Lorusso E; Bombardieri E; Ruello A; Viviani S; Molesti E; Trombetta CM; Manenti A; Montomoli E
    J Immunol Res; 2022; 2022():4813199. PubMed ID: 36093434
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The challenge of avidity determination in SARS-CoV-2 serology.
    Bauer G; Struck F; Schreiner P; Staschik E; Soutschek E; Motz M
    J Med Virol; 2021 May; 93(5):3092-3104. PubMed ID: 33565617
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vaccination versus infection with SARS-CoV-2: Establishment of a high avidity IgG response versus incomplete avidity maturation.
    Struck F; Schreiner P; Staschik E; Wochinz-Richter K; Schulz S; Soutschek E; Motz M; Bauer G
    J Med Virol; 2021 Dec; 93(12):6765-6777. PubMed ID: 34387884
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vaccination with BNT162b2 and ChAdOx1 nCoV-19 Induces Cross-Reactive Anti-RBD IgG against SARS-CoV-2 Variants including Omicron.
    Gerges D; Kapps S; Hernández-Carralero E; Freire R; Aiad M; Schmidt S; Winnicki W; Reiter T; Pajenda S; Schmidt A; Sunder-Plassmann G; Wagner L
    Viruses; 2022 May; 14(6):. PubMed ID: 35746653
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The potential significance of high avidity immunoglobulin G (IgG) for protective immunity towards SARS-CoV-2.
    Bauer G
    Int J Infect Dis; 2021 May; 106():61-64. PubMed ID: 33713819
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human serum from SARS-CoV-2-vaccinated and COVID-19 patients shows reduced binding to the RBD of SARS-CoV-2 Omicron variant.
    Schubert M; Bertoglio F; Steinke S; Heine PA; Ynga-Durand MA; Maass H; Sammartino JC; Cassaniti I; Zuo F; Du L; Korn J; Milošević M; Wenzel EV; Krstanović F; Polten S; Pribanić-Matešić M; Brizić I; Baldanti F; Hammarström L; Dübel S; Šustić A; Marcotte H; Strengert M; Protić A; Piralla A; Pan-Hammarström Q; Čičin-Šain L; Hust M
    BMC Med; 2022 Mar; 20(1):102. PubMed ID: 35236358
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Barcoded Flow Cytometric Assay to Explore the Antibody Responses Against SARS-CoV-2 Spike and Its Variants.
    Vesper N; Ortiz Y; Bartels-Burgahn F; Yang J; de la Rosa K; Tenbusch M; Schulz S; Finzel S; Jäck HM; Eibel H; Voll RE; Reth M
    Front Immunol; 2021; 12():730766. PubMed ID: 34630410
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Variant-Associated Receptor Binding Domain (RBD) Mutations on the Susceptibility to Serum Antibodies Elicited by Coronavirus Disease 2019 (COVID-19) Infection or Vaccination.
    Chen LL; Lu L; Choi CY; Cai JP; Tsoi HW; Chu AW; Ip JD; Chan WM; Zhang RR; Zhang X; Tam AR; Lau DP; To WK; Que TL; Yip CC; Chan KH; Cheng VC; Yuen KY; Hung IF; To KK
    Clin Infect Dis; 2022 May; 74(9):1623-1630. PubMed ID: 34309648
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evolution of Anti-RBD IgG Avidity following SARS-CoV-2 Infection.
    Tauzin A; Gendron-Lepage G; Nayrac M; Anand SP; Bourassa C; Medjahed H; Goyette G; Dubé M; Bazin R; Kaufmann DE; Finzi A
    Viruses; 2022 Mar; 14(3):. PubMed ID: 35336940
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correlation Analysis of Anti-SARS-CoV-2 RBD IgG and Neutralizing Antibody against SARS-CoV-2 Omicron Variants after Vaccination.
    Takheaw N; Liwsrisakun C; Chaiwong W; Laopajon W; Pata S; Inchai J; Duangjit P; Pothirat C; Bumroongkit C; Deesomchok A; Theerakittikul T; Limsukon A; Tajarernmuang P; Niyatiwatchanchai N; Trongtrakul K; Kasinrerk W
    Diagnostics (Basel); 2022 May; 12(6):. PubMed ID: 35741126
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Omicron infection increases IgG binding to spike protein of predecessor variants.
    Mahalingam G; Periyasami Y; Arjunan P; Subaschandrabose RK; Mathivanan TV; Mathew RS; Devi RKT; Premkumar PS; Muliyil J; Srivastava A; Moorthy M; Marepally S
    J Med Virol; 2023 Feb; 95(2):e28419. PubMed ID: 36546401
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-SARS-CoV-2 Immunoglobulin Isotypes, and Neutralization Activity Against Viral Variants, According to BNT162b2-Vaccination and Infection History.
    Tarkowski M; de Jager W; Schiuma M; Covizzi A; Lai A; Gabrieli A; Corbellino M; Bergna A; Ventura CD; Galli M; Riva A; Antinori S
    Front Immunol; 2021; 12():793191. PubMed ID: 34975897
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Glycosylated RBD Protein Induces Enhanced Neutralizing Antibodies against Omicron and Other Variants with Improved Protection against SARS-CoV-2 Infection.
    Shi J; Zheng J; Tai W; Verma AK; Zhang X; Geng Q; Wang G; Guan X; Malisheni MM; Odle AE; Zhang W; Li F; Perlman S; Du L
    J Virol; 2022 Sep; 96(17):e0011822. PubMed ID: 35972290
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neutralization of SARS-CoV-2 requires antibodies against conformational receptor-binding domain epitopes.
    Gattinger P; Niespodziana K; Stiasny K; Sahanic S; Tulaeva I; Borochova K; Dorofeeva Y; Schlederer T; Sonnweber T; Hofer G; Kiss R; Kratzer B; Trapin D; Tauber PA; Rottal A; Körmöczi U; Feichter M; Weber M; Focke-Tejkl M; Löffler-Ragg J; Mühl B; Kropfmüller A; Keller W; Stolz F; Henning R; Tancevski I; Puchhammer-Stöckl E; Pickl WF; Valenta R
    Allergy; 2022 Jan; 77(1):230-242. PubMed ID: 34453317
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibody response to SARS-CoV-2 for more than one year - kinetics and persistence of detection are predominantly determined by avidity progression and test design.
    Scheiblauer H; Nübling CM; Wolf T; Khodamoradi Y; Bellinghausen C; Sonntagbauer M; Esser-Nobis K; Filomena A; Mahler V; Maier TJ; Stephan C
    J Clin Virol; 2022 Jan; 146():105052. PubMed ID: 34920374
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High-Resolution Linear Epitope Mapping of the Receptor Binding Domain of SARS-CoV-2 Spike Protein in COVID-19 mRNA Vaccine Recipients.
    Nitahara Y; Nakagama Y; Kaku N; Candray K; Michimuko Y; Tshibangu-Kabamba E; Kaneko A; Yamamoto H; Mizobata Y; Kakeya H; Yasugi M; Kido Y
    Microbiol Spectr; 2021 Dec; 9(3):e0096521. PubMed ID: 34756082
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Determinants of protection against SARS-CoV-2 Omicron BA.1 and Delta infections in fully vaccinated outpatients.
    Roy A; Saade C; Josset L; Clément B; Morfin F; Destras G; Valette M; Icard V; Billaud G; Oblette A; Debombourg M; Garrigou C; Brengel-Pesce K; Generenaz L; Saker K; Hernu R; Pozzetto B; Lina B; Trabaud MA; Trouillet-Assant S; Bal A
    J Med Virol; 2023 Aug; 95(8):e28984. PubMed ID: 37503561
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neutralizing Potency of Prototype and Omicron RBD mRNA Vaccines Against Omicron Variant.
    Zang J; Yin Y; Xu S; Qiao W; Liu Q; Lavillette D; Zhang C; Wang H; Huang Z
    Front Immunol; 2022; 13():908478. PubMed ID: 35844601
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vaccine based on folded receptor binding domain-PreS fusion protein with potential to induce sterilizing immunity to SARS-CoV-2 variants.
    Gattinger P; Kratzer B; Tulaeva I; Niespodziana K; Ohradanova-Repic A; Gebetsberger L; Borochova K; Garner-Spitzer E; Trapin D; Hofer G; Keller W; Baumgartner I; Tancevski I; Khaitov M; Karaulov A; Stockinger H; Wiedermann U; Pickl WF; Valenta R
    Allergy; 2022 Aug; 77(8):2431-2445. PubMed ID: 35357709
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.